Indegene announced strong Q2 FY26 results, marked by a 17.1% YoY revenue growth in INR terms, reaching INR 8,042 Mn. The company highlighted strategic initiatives focused on business capability enhancement and deeper client engagement. Key business highlights include 76 active client relationships and a continued focus on innovation and technology integration.
Financial Performance Highlights
Indegene reported robust financial results for Q2 FY26:
- Revenue from Operations: INR 8,042 Mn (17.1% YoY growth in INR terms)
- Adjusted EBITDA: INR 1,461 Mn (15.3% YoY growth)
- Profit After Tax (PAT): INR 1,021 Mn (11.3% YoY growth)
For the first half of FY26 (H1 FY26), Indegene showcased the following:
- Revenue from Operations: INR 15,650 Mn (14.8% YoY growth in INR terms)
- Adjusted EBITDA: INR 3,004 Mn (15.7% YoY growth)
- PAT: INR 2,185 Mn (21.8% YoY growth)
Business Segment Overview
The company’s revenue mix remains stable, with key contributions from:
- Enterprise Medical Solutions: 60.6%
- Enterprise Commercial Solutions: 27.9%
- Brand Activation: 7.9%
Client and Geographic Performance
- Active Client Relationships: 76
- Clients with $1 Million+ Revenue: 40
- Revenue from Top 20 Global Biopharma Companies: 63%
Geographically, revenue contributions are led by North America at 69.6%, followed by Europe at 27.0%.
Strategic Initiatives and Outlook
Indegene is focused on deepening engagement with large pharma customers and broadening its reach. Key strategic initiatives include:
- Strengthening ECS capabilities with senior talent additions in data, analytics, and content.
- Implementing the Malcolm Baldrige Model to drive operational excellence.
Source: BSE